TMCnet News
Arrowhead to Present at Upcoming ConferencesPASADENA, Calif. --(Business Wire)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the Company will present at upcoming investor and scientific conferences. Investor Conferences
Investors may access a live and archived audio webcast of these presentations on the Company's website at http://ir.arrowheadresearch.com/events.cfm. Scientific Conferences
About Arrowhead Research Corporation Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology. For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter (News - Alert) @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm. Source (News - Alert): Arrowhead Research Corporation
|